Ivy Sports Medicine Has First Implantation of the Collagen Meniscus Implant (CMI)
The CMI® will officially be introduced to the US market at this year's Arthroscopy Association of North America (AANA) Fall Course at The Gaylord Texan in Dallas TX, on November 12th-14th, 2015.
Montvale Township, NJ, November 12, 2015 (Newswire.com) - Ivy Sports Medicine, an orthopedics company focused on the repair and preservation of the meniscus, announced the first implantation of its Collagen Meniscus Implant (CMI) in the US. The surgery was performed by Dr. Wayne Gersoff, an orthopedic surgeon from Denver, Colorado who specializes in sports medicine and cartilage restoration. “The CMI provides physicians with a new option when faced with an irreparable meniscus tear or a failed meniscectomy that results in segmental loss of meniscal tissue,” said Dr. Gersoff. The Collagen Meniscus Implant (CMI) is a biocompatible scaffold made of highly purified collagen that can be used to reinforce and repair a meniscus defect following partial meniscectomy or for irreparable meniscus tears. The implant has the general shape of the human meniscus and is trimmed by the surgeon to match the size of the meniscal defect. The implant is inserted via a minimally invasive procedure and sutured in place to the native meniscus.
“We are very excited to have the CMI available for physicians and patients in the U.S. Our company was founded on the idea that preservation of the meniscus was a large and growing treatment trend and the CMI offers physicians the ability to treat patients with previously irreparable meniscus injuries,” said Bob Pangia, Chairman and CEO of Ivy Sports Medicine. “We are seeing a shift in the medical community towards preserving the meniscus to prevent degenerative changes to the articular cartilage.” Approximately 20% of meniscal injuries result in a meniscus repair or meniscus transplantation, while 80% are treated via partial or total meniscectomies. Once a portion of the meniscus is removed, the articular cartilage can experience excessive stress which may lead to arthritic changes and the onset of osteoarthritis (OA). Due to the long-term degenerative nature of OA, patients may experience increased pain and reduced function. If the pain is too severe, patients may become candidates for a total knee replacement. “The availability of the CMI in the US, offers physicians another option when faced with the difficult decision to repair or resect the meniscus”, said Mr. Pangia.
The CMI will officially be introduced to the US market at this year’s Arthroscopy Association of North America (AANA) Fall Course at The Gaylord Texan in Dallas TX, on November 12th-14th, 2015. The CMI is the only collagen scaffold for repair and reinforcement of the meniscus that has been cleared for sale in the US. With over 20 years of clinical experience in more than 6,000 CMI cases worldwide and 42 peer reviewed publications, the CMI is uniquely positioned to make a significant impact in the competitive meniscus repair segment within the overall sports medicine market.
About IVY Sports Medicine:
Founded in late 2011, Ivy Sports Medicine is a privately held orthopedic device company that develops, manufactures and markets innovative tissue growth and repair products that focus on preservation of the meniscus.
For more information on Ivy Sports Medicine, the Collagen Meniscus Implant and the meniscus repair portfolio, please visit www.ivysportsmed.com, or email info.US@ivysportsmed.com.
This press release contains information that constitutes forward-looking statements. Forward-looking statements contained in this press release include intent, belief and expectations by the management team of Ivy Sports Medicine with respect to current and future business operations. Such statements reflect various assumptions, which may or may not prove to be correct. No representations or warranties are made as to the accuracy of any such statements.